Publications by authors named "Michael E Kuligowski"
Article Synopsis
- Atopic dermatitis (AD) affects around 7% of adolescents worldwide, and a new topical cream containing ruxolitinib (a JAK 1/JAK2 inhibitor) showed promise in treating this condition in two phase 3 trials.
- The study focused on patients aged 12-17 and assessed the safety and effectiveness of 1.5% ruxolitinib cream compared to a placebo, with evaluations at the 8-week mark and during a long-term safety period of up to 52 weeks.
- Results indicated that a significant portion of participants using the 1.5% cream experienced substantial improvements in skin condition and itchiness, with 89% choosing to continue the treatment in the long-term
Background: Therapies for children with atopic dermatitis (AD) have safety and tolerability concerns that may limit long-term use. Ruxolitinib cream, a Janus kinase (JAK) inhibitor, is effective and well tolerated in adolescents and adults with AD.
Objective: To analyze the safety and tolerability of ruxolitinib cream in pediatric patients.
Background: Ruxolitinib cream demonstrated safety and efficacy over 8 weeks in 2 double-blind phase 3 atopic dermatitis studies (NCT03745638/NCT03745651).
Objective: To evaluate long-term safety (LTS) and disease control with ruxolitinib cream.
Methods: Patients initially randomized to twice-daily 0.
Rapid pruritus reduction with ruxolitinib cream treatment in patients with atopic dermatitis.
J Eur Acad Dermatol Venereol
January 2023
Background: Ruxolitinib cream is a topical formulation of ruxolitinib, a Janus kinase (JAK) 1/JAK2 inhibitor.
Objectives: To report timing and magnitude of effect of ruxolitinib cream on itch in patients with atopic dermatitis (AD), a highly pruritic inflammatory skin disease.
Methods: Two phase 3 trials (TRuE-AD1 [NCT03745638]/TRuE-AD2 [NCT03745651]) enrolled patients aged ≥12 years with AD for ≥2 years, Investigator's Global Assessment score of 2 or 3, and 3%-20% affected body surface area.
Background: Pathogenesis of atopic dermatitis (AD) involves the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway. A cream formulation of ruxolitinib, a potent selective JAK1/JAK2 inhibitor, was developed for topical delivery.
Method: Pharmacokinetic data were obtained from three double-blind, vehicle-controlled studies in patients with AD: a phase II study with ruxolitinib cream 0.
Background: Ruxolitinib (RUX) cream demonstrated potent anti-inflammatory and antipruritic efficacy in a phase 2 study in adults with atopic dermatitis (AD).
Objective: To evaluate 8-week efficacy and safety in 2 phase 3 studies of RUX cream in patients with AD.
Methods: Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (NCT03745638) and Study 2 (NCT03745651) enrolled patients aged ≥12 years with AD for ≥2 years, an Investigator's Global Assessment score of 2/3, and 3%-20% affected body surface area.
Background: Atopic dermatitis (AD), a chronic, highly pruritic skin disorder, impairs quality of life (QoL). Janus kinase inhibitors suppress inflammatory and pruritus-associated cytokine signaling in AD.
Objective: To report the effects of ruxolitinib (RUX) cream on itch and QoL in AD.
Background: Atopic dermatitis (AD) is a highly pruritic chronic inflammatory skin disorder. Ruxolitinib, a selective inhibitor of Janus kinase 1 and Janus kinase 2, potently suppresses cytokine signaling involved in AD pathogenesis.
Objective: We sought to evaluate the efficacy and safety of ruxolitinib (RUX) cream in adults with AD.